86.22

3.56% 2.96

After Hours: 85.89 -0.33 -0.38%

Bright Minds Biosciences Inc (DRUG)

Overview News Price History Discussions Forecast Stock Split

Bright Minds Biosciences Inc stock is traded at $86.22, with a volume of 178.00K. It is up +3.56% in the last 24 hours and up +20.65% over the past month. Bright Minds Biosciences Inc is focused on developing novel, transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult-to-treat disorders such as resistant epilepsy, treatment-resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.

Previous Close:

$83.26

Open:

$83.6

24h Volume:

178.00K

Relative Volume:

1.19

Market Cap:

$843.85M

Revenue:

Net Income/Loss:

$-14.23M

P/E Ratio:

-44.45

EPS:

-1.9396

Net Cash Flow:

$-9.44M

1W Performance:

-3.11%

1M Performance:

+20.65%

6M Performance:

+65.27%

1Y Performance:

+176.26%

1-Day Range:

$81.35

$87.36

1-Week Range:

$81.29

$91.00

52-Week Range:

$23.18

$123.75

Bright Minds Biosciences Inc Stock (DRUG) Company Profile

Name

Bright Minds Biosciences Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

Address

Employee

Twitter

Next Earnings Date

2026-05-21

Latest SEC Filings

DRUG's Discussions on Twitter

Compare DRUG vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DRUG Bright Minds Biosciences Inc	86.22	814.88M	0	-14.23M	-9.44M	-1.9396
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-13-26	Initiated	Jefferies	Buy
Sep-08-25	Initiated	BTIG Research	Buy
May-13-25	Initiated	TD Cowen	Buy
May-07-25	Initiated	Chardan Capital Markets	Buy
Jan-23-25	Initiated	Piper Sandler	Overweight
Jan-10-25	Initiated	Cantor Fitzgerald	Overweight
Jan-10-25	Initiated	H.C. Wainwright	Buy
Nov-26-24	Initiated	Robert W. Baird	Outperform

View All

Bright Minds Biosciences Inc Stock (DRUG) Latest News

May 04, 2026

This Insider Has Just Sold Shares In Bright Minds Biosciences - simplywall.st

May 04, 2026

May 01, 2026

DRUG SEC FilingsBright Minds Biosciences Inc 10-K, 10-Q, 8-K Forms - Stock Titan

May 01, 2026

Apr 30, 2026

Cormorant sells $9.78m in Bright Minds Biosciences stock - Investing.com UK

Apr 30, 2026

[SCHEDULE 13G/A] BRIGHT MINDS BIOSCIENCES INC. Amended Passive Investment Disclosure - Stock Titan

Apr 30, 2026

Insider Selling: Bright Minds Biosciences (NASDAQ:DRUG) Major Shareholder Sells 109,331 Shares of Stock - MarketBeat

Apr 30, 2026

Bright Minds Biosciences (DRUG) holder sells 109,331 shares in open market - Stock Titan

Apr 30, 2026

Apr 27, 2026

Bright Minds announces ATM offering up to $100 million - MSN

Apr 27, 2026

Apr 26, 2026

How Bright Minds Biosciences Inc. (DRUG) Affects Rotational Strategy Timing - Stock Traders Daily

Apr 26, 2026

Apr 23, 2026

Bright Minds (DRUG) Year-Ahead Outlook | Q4 2025: Earnings ReportSurprise Score - Cổng thông tin điện tử tỉnh Tây Ninh

Apr 23, 2026

Apr 22, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Apr 22, 2026

Top 3 Canadian Biotech Stocks in 2026 - Investing News Network

Apr 22, 2026

Apr 18, 2026

Bright Minds Biosciences (NASDAQ:DRUG) Downgraded to Sell Rating by Wall Street Zen - MarketBeat

Apr 18, 2026

Apr 16, 2026

Shroom stocks rise as Trump is said to sign executive order on psychedelic drug - Seeking Alpha

Apr 16, 2026

Apr 15, 2026

Bright Minds Biosciences Inc. (NASDAQ:DRUG) Sees Significant Growth in Short Interest - MarketBeat

Apr 15, 2026

(DRUG) and the Role of Price-Sensitive Allocations - Stock Traders Daily

Apr 15, 2026

Apr 13, 2026

Bright Minds Biosciences (NASDAQ:DRUG) Earns Buy Rating from Analysts at Jefferies Financial Group - MarketBeat

Apr 13, 2026

Jefferies initiates Bright Minds stock with buy on epilepsy drug By Investing.com - Investing.com South Africa

Apr 13, 2026

Jefferies initiates Bright Minds stock with buy on epilepsy drug - Investing.com

Apr 13, 2026

Apr 09, 2026

Total debt per share of Bright Minds Biosciences Inc. – NEO:DRUG - TradingView

Apr 09, 2026

Apr 07, 2026

Certain RSUs of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com

Apr 07, 2026

Certain Options of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com

Apr 07, 2026

7,787,161 Common Shares of Bright Minds Biosciences Inc. are subject to a Lock-Up Agreement Ending on 8-APR-2026. - marketscreener.com

Apr 07, 2026

Bright Minds Biosciences (NASDAQ:DRUG) Shares Gap UpHere's Why - MarketBeat

Apr 07, 2026

Apr 06, 2026

Pullback Watch: Is Bright Minds Biosciences Inc a cyclical or defensive stockRecession Risk & Target Return Focused Stock Picks - baoquankhu1.vn

Apr 06, 2026

Bright Minds Biosciences (NASDAQ:DRUG) Trading 7.4% HigherWhat's Next? - MarketBeat

Apr 06, 2026

Sentiment Watch: What is PROVs 5 year growth outlookWeekly Profit Recap & Proven Capital Preservation Methods - baoquankhu1.vn

Apr 06, 2026

Apr 04, 2026

Responsive Playbooks and the DRUG Inflection - Stock Traders Daily

Apr 04, 2026

Apr 01, 2026